Cardionews

American Heart Association Leads Efforts To Reduce Preventable Deaths And Rehospitalizations For Heart Failure Patients
An article, "Rehospitalizations among Patients in the Medicare," published in The New England Journal of Medicine, found that almost 20 percent of 11,855,702 Medicare beneficiaries discharged from a hospital were rehospitalized within 30 days. The annual cost to Medicare for this rehospitalization is $17.4 billion. Of the disease states detailed in the study, heart failure costs the U.S.

Revealing The Source Of Major Health Benefits In Olive Oil
Scientists have pinned down the constituent of olive oil that gives greatest protection from heart attack and stroke. In a study of the major antioxidants in olive oil, Portuguese researchers showed that one, DHPEA-EDA, protects red blood cells from damage more than any other part of olive oil.

Polypill Could Reduce Multiple Risk Factors For Cardiovascular Disease (Tips Study)
A polypill containing a statin, aspirin, and three blood pressure-lowering drugs could massively reduce future incidence of heart attack and stroke in currently healthy people. The findings of the TIPS* study are discussed in an Article published Online First and in an upcoming edition of The Lancet. Publication of the Article coincides with the announcement of the findings at the American College of Cardiology (ACC) meeting in Florida, USA.

Scientists Discover That Heart Muscle Cells Are Renewed
Research led by scientists in Sweden found that our heart muscle cells are renewed over our lifetime and we are not limited to those we are born with. They believe the discovery opens a door to treatments that could replace damaged heart tissue with new cells. The study was the work of Professor Jonas Frisén of the Karolinska Institutet, in Stockholm, Sweden, and colleagues and is published online in the 3 April issue of Science.

Decreasing Markers Of Inflammation Is As Important For Statin Action As Decreasing Ldl Cholesterol (Jupiter Study)
A follow-up study on the JUPITER* trial has revealed that a key component of the action of statins is reduction of high sensitivity c-reactive protein (hsCRP), a marker of inflammation, as well as reducing levels of bad cholesterol. The findings are published in an Article published Online First and in an upcoming edition of The Lancet. Publication of the Article coincides with the announcement of the findings at the American College of Cardiology (ACC) meeting in Florida, USA.